Lena-Christin Conradi
Overview
Explore the profile of Lena-Christin Conradi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
67
Citations
1982
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Richter K, Wrage M, Krekeler C, De Oliveira T, Conradi L, Menck K, et al.
EMBO Mol Med
. 2025 Feb;
17(3):395-413.
PMID: 39948421
Colorectal cancer (CRC) is a major health problem, with an alarming increase of early-onset CRC (EO-CRC) cases among individuals under 50 years of age. This trend shows the urgent need...
2.
Irmer B, Wlochowitz D, Krekeler C, Richter K, Chandrabalan S, Bayerlova M, et al.
Mol Oncol
. 2025 Jan;
19(3):614-634.
PMID: 39825568
The transcriptomic classification of primary colorectal cancer (CRC) into distinct consensus molecular subtypes (CMSs) is a well-described strategy for patient stratification. However, the molecular nature of CRC metastases remains poorly...
3.
Tapia Contreras C, Falke J, Seifert D, Schneider C, Krauss L, Fang X, et al.
Mol Oncol
. 2024 Sep;
19(2):295-310.
PMID: 39253995
Pancreatic ductal adenocarcinoma (PDAC) has limited treatment options, emphasizing the urgent need for effective therapies. The predominant driver in PDAC is mutated KRAS proto-oncogene, KRA, present in 90% of patients....
4.
Lebas M, Chinigo G, Courmont E, Bettaieb L, Machmouchi A, Goveia J, et al.
Sci Adv
. 2024 Aug;
10(32):eadp6182.
PMID: 39121218
Endothelial cells (ECs) are highly plastic, capable of differentiating into various cell types. Endothelial-to-mesenchymal transition (EndMT) is crucial during embryonic development and contributes substantially to vascular dysfunction in many cardiovascular...
5.
Fan S, Fleischer J, Dokshokova L, Bohme L, Haas G, Schmitt A, et al.
Mol Ther Oncol
. 2024 Jul;
32(3):200828.
PMID: 39072289
To date, nearly one-quarter of colorectal cancer (CRC) patients develop liver metastases (CRCLM), and its aggressiveness can be correlated to defined histopathological growth patterns (HGP). From the three main HGPs...
6.
Edelmann M, Fan S, De Oliveira T, Goldhardt T, Sartorius D, Midelashvili T, et al.
Cancer Res Commun
. 2024 Jul;
4(8):2008-2024.
PMID: 39007350
Significance: Novel therapies to better treat colorectal cancer are necessary to improve patient outcomes. Therefore, in this study, we evaluated the combination of a metabolic inhibitor (3PO) and standard radiotherapy...
7.
Ferreira N, Kulkarni A, Agorku D, Midelashvili T, Hardt O, Legler T, et al.
Cell Oncol (Dordr)
. 2024 May;
48(1):101-122.
PMID: 38805131
Purpose: Pancreatic Ductal Adenocarcinoma (PDAC) remains a challenging disease due to its complex biology and aggressive behavior with an urgent need for efficient therapeutic strategies. To assess therapy response, pre-clinical...
8.
Isermann T, Schneider K, Wegwitz F, De Oliveira T, Conradi L, Volk V, et al.
bioRxiv
. 2024 Mar;
PMID: 38464125
The stress-associated molecular chaperone system is an actionable target in cancer therapies. It is ubiquitously upregulated in cancer tissues and enables tumorigenicity by stabilizing hundreds of oncoproteins and disturbing the...
9.
Conradi L, Haas G, Fleischer J, Ghadimi M
Zentralbl Chir
. 2024 Mar;
149(1):67-74.
PMID: 38442885
The multimodal treatment of rectal cancer has differentiated considerably over the last decade depending on the characteristics of the tumor and the patient's circumstances. Surgery continues to be an important...
10.
Sartorius D, Blume M, Fleischer J, Ghadimi M, Conradi L, De Oliveira T
Cancers (Basel)
. 2023 Nov;
15(21).
PMID: 37958298
Aside from surgical resection, locally advanced rectal cancer is regularly treated with neoadjuvant chemoradiotherapy. Since the concept of cancer treatment has shifted from only focusing on tumor cells as drivers...